אורנסיה 250 מ"ג - Orencia 250 mg: הבדלים בין גרסאות

ORENCIA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ORENCIA may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists. Polyarticular juvenile idiopathic arthritis:Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor. Orencia has not been studied in children under 6 years old.ORENCIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA).